Pharmacyte Biotech, Inc. Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Pharmacyte Biotech, Inc. (PMCB) on August 1, 2023. The company is incorporated in Nevada and its common stock trades on The Nasdaq Stock Market LLC. The report addresses a significant corporate governance event regarding the company's independent registered public accounting firm.
Key Financial Metrics
The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on the resignation of the company's auditor and does not contain financial statement data or performance metrics.
Material Changes
The primary material change disclosed is the resignation of Armanino LLP as the Company's independent auditor. The resignation is effective as of the earlier of the date a new firm is engaged or the filing of the Quarterly Report on Form 10-Q for the fiscal quarter ended January 31, 2024. The company has initiated a process to select a new accounting firm for the fiscal year ending April 30, 2024.
Outlook, Risks, and Management Commentary
- Reason for Resignation: Armanino LLP advised that the resignation is due solely to its decision to exit the practice of providing financial statement audit services to all public company engagements. It is not related to any actions taken by the Company.
- Audit History: Armanino's audit reports for the years ended April 30, 2023, and April 30, 2022, did not contain adverse opinions, disclaimers, or qualifications regarding uncertainty, scope, or accounting principles.
- Disagreements: There were no disagreements with Armanino on accounting principles, practices, disclosures, or auditing scope during the relevant periods.
- Management Action: The Board of Directors and Audit Committee did not participate in the auditor's decision to resign. The company has requested and received a letter from Armanino confirming agreement with the disclosures in this report.
Investor Verification Checklist
- Verify the timeline for the appointment of a new independent registered public accounting firm.
- Review the attached Exhibit 16.1 (Letter from Armanino LLP) for any additional context regarding the resignation.
- Monitor upcoming filings (specifically the 10-Q for the quarter ended January 31, 2024) to confirm the transition of audit responsibilities.
- Confirm that no undisclosed disagreements or reportable events exist between the company and the former auditor.